<DOC>
	<DOCNO>NCT02567370</DOCNO>
	<brief_summary>The purpose study find time take absorb , distribute , breakdown remove drug body , safety tolerability AMG 581 healthy participant subject schizophrenia .</brief_summary>
	<brief_title>Single-ascending Dose Study With Food-Effect Cohort Evaluate AMG 581</brief_title>
	<detailed_description>The purpose study evaluate safety , tolerability , pharmacokinetic profile single-ascending oral dos AMG 581 healthy subject subject diagnose schizophrenia schizoaffective disorder receive antipsychotic treatment . This placebo-controlled , single-ascending oral-dose study AMG 581 food-effect cohort . Approximately 70 subject enrol . This study enroll healthy subject 8 cohort ( Cohorts 1,2,3,4,5,6,8 9 ) , subject schizophrenia schizoaffective disorder receive antipsychotic medication single cohort ( Cohort 7 ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Provide inform consent prior initiation studyrelated procedure Male female subject ≥ 18 ≤ 45 year age time screen Nonnicotine nontobacco healthy subject No history relevant medical disorder BMI ≥ 18.0 ≤ 30.0 Nonreproductive female Males practice effect birth control Avoid tanning/direct sunlight Willing consume highfat meal Schizophrenia schizoaffective disorder PANSS score ≤ 4 point item ( i.e . conceptual disorganization , hallucinatory behavior , excitement , suspiciousness/persecution , hostility , depression , anxiety , disorientation , uncooperativeness , disturbance volition , poor impulse control ) / total score ≤ 80 point Females lactating/breastfeeding Pregnant partner male subject Tremor gait disturbance History hereditary shorten QT syndrome Malignancy tumor ( skin cancer ) History GI disease QTc ≥ 450 msec ≤ 380 msec Creatinine clearance &lt; 80 mL/min screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Schizophrenia Schizoaffective Disorder</keyword>
</DOC>